These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1998992)
1. Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses. Carfagna PF; Poma A; Wyrick SD; Holbrook DJ; Chaney SG Cancer Chemother Pharmacol; 1991; 27(5):335-41. PubMed ID: 1998992 [TBL] [Abstract][Full Text] [Related]
2. Effects of diethyldithiocarbamate (DDTC) on the plasma biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in Fischer 344 rats. Carfagna PF; Wyrick SD; Holbrook DJ; Chaney SG J Biochem Toxicol; 1991; 6(1):71-80. PubMed ID: 1652641 [TBL] [Abstract][Full Text] [Related]
3. In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Chaney SG; Wyrick S; Till GK Cancer Res; 1990 Aug; 50(15):4539-45. PubMed ID: 2196115 [TBL] [Abstract][Full Text] [Related]
4. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line. Chaney SG; Gibbons GR; Wyrick SD; Podhasky P Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140 [TBL] [Abstract][Full Text] [Related]
5. Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Gibbons GR; Wyrick S; Chaney SG Cancer Res; 1989 Mar; 49(6):1402-7. PubMed ID: 2924297 [TBL] [Abstract][Full Text] [Related]
6. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat. Thompson DC; Vaisman A; Sakata MK; Wyrick SD; Holbrook DJ; Chaney SG Cancer Chemother Pharmacol; 1995; 36(5):439-47. PubMed ID: 7634386 [TBL] [Abstract][Full Text] [Related]
7. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Mauldin SK; Gibbons G; Wyrick SD; Chaney SG Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241 [TBL] [Abstract][Full Text] [Related]
8. Biotransformations of oxaliplatin in rat blood in vitro. Luo FR; Wyrick SD; Chaney SG J Biochem Mol Toxicol; 1999; 13(3-4):159-69. PubMed ID: 10098901 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Luo FR; Wyrick SD; Chaney SG Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745 [TBL] [Abstract][Full Text] [Related]
10. Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat. Smith JH; Smith MA; Litterst CL; Copley MP; Uozumi J; Boyd MR Fundam Appl Toxicol; 1988 Jan; 10(1):45-61. PubMed ID: 3350229 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravenously injected [3H]tetrachloro(D,L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice. Kido Y; Khokhar AR; Siddik ZH Drug Metab Dispos; 1992; 20(5):673-8. PubMed ID: 1358571 [TBL] [Abstract][Full Text] [Related]
12. Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat. Carfagna PF; Chaney SG; Chang J; Holbrook DJ Fundam Appl Toxicol; 1990 May; 14(4):706-19. PubMed ID: 2163338 [TBL] [Abstract][Full Text] [Related]
13. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. Luo FR; Yen TY; Wyrick SD; Chaney SG J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):345-56. PubMed ID: 10219677 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice. Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287 [TBL] [Abstract][Full Text] [Related]
15. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). Chaney S Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue. Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402 [TBL] [Abstract][Full Text] [Related]
17. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat. Smith MA; Smith JH; Litterst CL; Copley MP; Uozumi J; Boyd MR Fundam Appl Toxicol; 1988 Jan; 10(1):62-72. PubMed ID: 3350230 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Luo FR; Wyrick SD; Chaney SG Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941 [TBL] [Abstract][Full Text] [Related]
19. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Luo FR; Wyrick SD; Chaney SG Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746 [TBL] [Abstract][Full Text] [Related]
20. Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II). Rischin D; Ling V Br J Cancer; 1996 Aug; 74(4):590-6. PubMed ID: 8761375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]